Advertisement

Topics

Clinical Trials About "A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g" RSS

19:05 EST 10th December 2018 | BioPortfolio

We list hundreds of Clinical Trials about "A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g" on BioPortfolio

We have published hundreds of A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g news stories on BioPortfolio along with dozens of A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g Clinical Trials and PubMed Articles about A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g Companies in our database. You can also find out about relevant A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g Drugs and Medications on this site too.

Showing "Study Xolair Peanut Allergic Subjects Previously Enrolled Study" Clinical Trials 1–25 of 51,000+

Extremely Relevant

A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g

This is a Phase IIb, multicenter, open-label study available to active (Xolair) and control (placebo) subjects who have completed their final visit (or early termination visit, if applicable) for Study Q2788g, who meet the eligibility criteria of this study, and who provide consent to participate in this study.


Xolair Enhances Oral Desensitization in Peanut Allergic Patients

This is a pilot feasibility study, using Xolair pretreatment for oral peanut desensitization.

Peanut Oral Immunotherapy

This is a study in which increasing amounts of peanut flour are given to the children who are peanut allergic to desensitize them to peanut. The hypothesis is that the peanut allergic patients would benefit from the desensitization by assuring that they will not have life-threatening allergic reactions to contaminating amounts of peanut in other foods and eventually it would cause them to lose their clinical sensitivity to peanut.


A Safety and Efficacy Study of Xolair in Peanut Allergy

This is a 38-week, randomized, double-blind, placebo-controlled, parallel group trial of approximately 150 patients who have a history of immediate hypersensitivity reaction to peanut protein.

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age

The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).

A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects

The study aims to assess the biological potency of the In-House Reference Preparation (IHRP) of peanut allergens extract by a quantitative Skin Prick Test (SPT) method in peanut-allergic subjects.

A Continued Access Protocol to Provide Xolair to Patients With Severe Allergic Asthma

This is a continued access protocol to provide subjects who have completed Genentech, Inc. Study Q2143g, Q2195g, or Q2461g or Novartis Pharmaceuticals Corporation Study CIGE025 0010E1 with continued Xolair treatment. Subject eligibility will be based on disease severity and asthma deterioration upon withdrawal of Xolair treatment. Subjects whose last Xolair dose was

Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients

This is a pilot randomized, double-blind, placebo controlled study which will be conducted at a single center. All participants will receive oral immunotherapy for their specific food allergies (limited to 5 of those food allergens in IND 14831). In a 3:1 ratio, 36 participants will receive Xolair for 16 weeks while 12 will receive corresponding placebo instead of Xolair. 12 controls will be enrolled who will receive no OIT and no Xolair.

Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults

The purpose of this study is to evaluate the safety and side effects of a study product that contains recombinant modified peanut proteins (EMP-123) in healthy and peanut-allergic participants. This is a first in human study. As of November 2009, this study is no longer recruiting healthy volunteers and will only be recruiting individuals with peanut allergies.

Double Blind Peanut Sublingual Immunotherapy

The specific aim of this study is to desensitize peanut-allergic subjects with peanut allergen-specific, sublingual immunotherapy (SLIT) by placing drops of peanut protein under the tongue which will be absorbed. The hypothesis is that peanut SLIT will desensitize patients with peanut allergic reactions by changing the subject's immune system to adapt to peanuts.

Early Life Origins of the Food Allergy Epidemic

The purpose of this study is to determine if avoidance of peanut by children with positive allergy testing to peanut in the first 5 years of life increases the likelihood of developing a persistent peanut allergy by age 5 years. To answer this question, the investigators need to determine which children with positive allergy testing to peanut have reactions after eating peanut (allergic to peanut) and which are able to tolerate eating peanut (not allergic). The investiga...

Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using (CPNA) Peanut OIT Safety Follow-On Study

This is a multi-center, open-label, follow-on study to gather additional information on the safety and tolerability of oral desensitization with CPNA in the subjects who participated in ARC001.

Immunotherapy for Peanut Allergy

Currently, when a food allergy is diagnosed, the "standard of care" is strict avoidance of the allergic food and ready access to self-injectable epinephrine. Yet, accidental ingestions do occur. Unfortunately, for a ubiquitous food such as peanut, the possibility of an inadvertent ingestion is great. It is estimated that over 50% of individuals who are allergic to peanuts will have an accidental reaction to peanuts over a 2-year period. The purpose of this study is to determin...

Take Away Food Allergy; Inducing Tolerance in Children Allergic to Peanut

The purpose of the study is to identify prognostic markers and possible success rate of tolerance induction to peanut allergens in children allergic to peanut.

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children

This is a multicenter, randomized, double-blind, placebo-controlled safety study of AR101 using the characterized oral desensitization immunotherapy (CODIT ™) regimen in peanut-allergic children.

Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children

This is an open-label, follow-up study for subjects who completed the PEPITES study. Subjects will be offered enrollment in this follow-up study to receive Viaskin Peanut 250 μg for 2 additional years if they were previously on active treatment in the PEPITES study, or for 3 years if they were on placebo in the PEPITES study.

Understanding How the Immune System Responds to Viruses in Peanut Allergic Children Undergoing Peanut Oral Immunotherapy

The purpose of this study is to find out if there is a way to treat children with peanut allergy to help lower the risk of severe allergic reactions and also cause them to lose their allergy to peanuts and to understand what happens to their immune systems when they have viral infections while on therapy. The approach we will use to treat peanut allergy in this study is a process called desensitization. We think that children with a peanut allergy receiving peanut oral immuno...

Peanut Oral Immunotherapy Study of Early Intervention for Desensitization

The purpose of this study is to determine the efficacy and safety of AR101 in peanut‑allergic children aged 1 to < 4 years.

Oral Peanut Immunotherapy

Peanut allergy is one of the most serious food allergies because of its life long persistence, and the potential for severe allergic reactions. Effective oral immunotherapy would benefit patients by reducing the likelihood that they will have life-threatening accidental allergic reactions. This research study is being done to develop an effective oral immunotherapy treatment for patients with peanut allergy.

Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

To compare the HRQOL of AR101 characterized oral desensitization immunotherapy (CODIT™) in combination with standard of care (peanut avoidance, education) versus standard of care alone in peanut-allergic subjects aged 4 to 17 years.

Identification of Anaphylactogenic Antibodies in Peanut Allergy

This project intends the analysis and profiling of specific antibodies against major peanut allergens in peanut allergic individuals and molecular cloning of human antibodies against major peanut allergens.

Xolair Treatment for Milk Allergic Children

This is a pilot feasibility study, using Xolair pretreatment for oral milk desensitization. The major assessment will be safety, and the investigators will evaluate for any type of reaction, including allergic reactions that occur during the course of the study.

A Study Evaluating the Persistency of Response With or Without Xolair After Long-Term Therapy

This is a randomized, double-blind, placebo-controlled, two-armed, one-year study of patients who have completed the EXCELS study (NCT00252135) and have been treated with Xolair for 5 or more years.

Oral Immunotherapy (OIT) for Peanut Allergy

Peanut allergy is known to cause severe anaphylactic reactions.The goal of this proposal is to produce a new treatment that would benefit subjects who have peanut allergy by lowering the risk of anaphylactic reactions (desensitization), and changing the peanut-specific immune response in subjects who have peanut allergy (tolerance).

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Pla

The purpose of this study is to evaluate the safety and tolerability of ASP0892 after intradermal (ID) injection in adolescent participants with peanut allergy.


More From BioPortfolio on "A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g"

Advertisement
Quick Search
Advertisement
Advertisement